Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
Advances in Minimal Residual Disease Testing in Myeloma Meeting
Advances in Minimal Residual Disease Testing in Myeloma Meeting
On July 10 in NYC, the MMRF helped host the “Advances in Minimal Residual Disease Testing in Multiple Myeloma” meeting at Memorial Sloan Kettering Cancer Center. This meeting brought together representatives from the US Food and Drug Administration (FDA), National Cancer Institute (NCI), and the biotechnology/pharmaceutical industry, as well as key opinion leaders to discuss the latest developments around minimal residual disease (MRD) in multiple myeloma.
On July 10 in NYC, the MMRF helped host the “Advances in Minimal Residual Disease Testing in Multiple Myeloma” meeting at Memorial Sloan Kettering Cancer Center. This meeting brought together representatives from the US Food and Drug Administration (FDA), National Cancer Institute (NCI), and the biotechnology/pharmaceutical industry, as well as key opinion leaders to discuss the latest developments around minimal residual disease (MRD) in multiple myeloma. The meeting was organized by Dr. Ola Landgren, MD, PhD, Chief Myeloma Service, Memorial Sloan Kettering Cancer Center, Professor of Medicine at the Weill Cornell Medical College, and Peter Brodhead, Chief, CME Office, Office of Physician-in Chief, Memorial Sloan Kettering Cancer Center.
During the first portion of this meeting, participants reviewed the advances and new data from ongoing trials that have emerged in the last 12 months since the last meeting in the field of MRD testing for myeloma patients.
Next, a debate session tackled the following questions:
- Should MRD be an endpoint for all clinical trials for myeloma?
- Is MRD ready for prime time in standard clinical care?
- Is MRD ready as a regulatory endpoint in myeloma?
During the last portion of the meeting, participants worked on formulating a consensus around uniform MRD testing criteria and laying a path for the use of MRD in clinical trials as well as in routine care. The day closed with a live webcast that recapped the deliberations and recommendations from the assembled participants. The goal of this meeting was to produce recommendations and an action plan on how to move forward with MRD testing in multiple myeloma, now.
From left to right, Dr. Gary Kelloff, NCI; Dr. Ola Landgren, Memorial Sloan Kettering Cancer Center; Dr. Nicole Gormley, FDA
Dr. Gary Kelloff, NCI and Walter Capone, CEO MMRF
Dr. Gareth Morgan, UAMS, Dr. Guenther Koehne and Dr. Ola Landgren, Memorial Sloan Kettering Cancer Center
The audience looks on as Dr. Tahamtan Ahmadi from Janssen Pharmaceuticals describes his “dream” MRD clinical study.
Click Here to download the program book.
Click Here to watch the live stream from the meeting.
The MMRF gratefully acknowledges our corporate sponsors:
